美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · PRME近 30 天 2 則 · 第 1 / 1 頁
- 體內基因編輯市場規模、佔有率及趨勢分析 - 全球機會分析與產業預測 (2026-2036)In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
- 基因編輯巨頭及其競爭對手飆升 邁向突破Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
- Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
- Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Scribe’s Genetic Editing Aims to Prevent Heart Attacks
- Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
- Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
- Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)
- Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics
- Cathie Wood Dumps AMD, Doubles Down on Meta Stock
- Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically?
- Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle
- Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
- Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
- Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
- Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。